CA2692412C - Treatment for anxiety - Google Patents

Treatment for anxiety Download PDF

Info

Publication number
CA2692412C
CA2692412C CA2692412A CA2692412A CA2692412C CA 2692412 C CA2692412 C CA 2692412C CA 2692412 A CA2692412 A CA 2692412A CA 2692412 A CA2692412 A CA 2692412A CA 2692412 C CA2692412 C CA 2692412C
Authority
CA
Canada
Prior art keywords
seq
anxiety
patient
peptide
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2692412A
Other languages
English (en)
French (fr)
Other versions
CA2692412A1 (en
Inventor
Andrew Tasker
Michael Tymianski
Kenneth Mendoza
Michael P. Belmares
David Garman
Peter S. Lu
Tracy Doucette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Publication of CA2692412A1 publication Critical patent/CA2692412A1/en
Application granted granted Critical
Publication of CA2692412C publication Critical patent/CA2692412C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2692412A 2007-07-03 2008-07-02 Treatment for anxiety Active CA2692412C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94789207P 2007-07-03 2007-07-03
US60/947,892 2007-07-03
PCT/US2008/069085 WO2009006548A2 (en) 2007-07-03 2008-07-02 Treatment for anxiety

Publications (2)

Publication Number Publication Date
CA2692412A1 CA2692412A1 (en) 2009-01-08
CA2692412C true CA2692412C (en) 2017-02-07

Family

ID=40226818

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2692412A Active CA2692412C (en) 2007-07-03 2008-07-02 Treatment for anxiety

Country Status (10)

Country Link
US (2) US8008253B2 (enExample)
EP (1) EP2175873B1 (enExample)
JP (2) JP5775303B2 (enExample)
KR (1) KR101604428B1 (enExample)
CN (1) CN101827604B (enExample)
AU (1) AU2008272903B2 (enExample)
CA (1) CA2692412C (enExample)
DK (1) DK2175873T3 (enExample)
ES (1) ES2555172T3 (enExample)
WO (1) WO2009006548A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
JP6005357B2 (ja) * 2008-05-16 2016-10-12 ノノ インコーポレイテッド てんかんの治療
EP2334315B1 (en) 2008-09-03 2023-01-18 NoNO Inc. Agents and methods for treatment of pain
EP2841063A2 (en) * 2012-04-27 2015-03-04 Indiana University Research and Technology Corporation Compositions and methods for treating ptsd and related diseases
CN105705605B (zh) 2013-11-05 2018-07-31 三菱化学株式会社 粘合剂组合物
WO2015137178A1 (ja) 2014-03-10 2015-09-17 三菱樹脂株式会社 画像表示装置構成用積層体の製造方法
CN114057895A (zh) * 2014-05-28 2022-02-18 诺诺公司 TAT-NR2B9c的氯盐
ES2843724T3 (es) 2015-11-30 2021-07-20 Inst Nat Sante Rech Med Antagonistas de NMDAR para el tratamiento de la angiogénesis tumoral
WO2017138544A1 (ja) 2016-02-08 2017-08-17 三菱ケミカル株式会社 透明両面粘着シート及び粘着シート積層体
TWI799372B (zh) 2016-02-08 2023-04-21 日商三菱化學股份有限公司 透明雙面黏著片及黏著片積層體
CN107312069B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
DK3450448T3 (da) 2016-04-27 2021-06-07 Biocells Beijing Biotech Co Ltd Terapeutisk peptid til excitatorisk neurotoksicitets-relaterede skader
CN106632601B (zh) * 2016-11-16 2020-10-20 中国科学院昆明动物研究所 一种阻断突触长时程增强（ltp）的短肽及其应用
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
JP7073486B2 (ja) * 2017-09-30 2022-05-23 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
CN114641484B (zh) * 2019-11-05 2024-08-09 国立大学法人京都大学 肽、组合物及治疗、预防或改善心境障碍的方法
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂
CN113735938B (zh) 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723838B1 (en) * 1998-04-22 2004-04-20 Johns Hopkins University Signal transducing synaptic molecules and uses thereof
US6942981B1 (en) * 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
FI20012082A0 (fi) * 2001-10-26 2001-10-26 Paeivi Liesi Biologisesti aktiiviset peptidit hermovauroiden korjaamiseksi
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
EP1578365A4 (en) * 2002-11-14 2009-09-23 Arbor Vita Corp MOLECULAR INTERACTIONS IN NEURONS
GB0303613D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
US20050084880A1 (en) * 2003-07-11 2005-04-21 Ronald Duman Systems and methods for diagnosing & treating psychological and behavioral conditions
US20070105902A1 (en) * 2003-11-12 2007-05-10 Lindsley Craig W 4-Phenyl piperdine sulfonyl glycine transporter inhibitors
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
US20060167075A1 (en) * 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
TW200640529A (en) * 2005-02-28 2006-12-01 Thomas Christian Lines Composition for treating mental health disorders
EP1910552A4 (en) * 2005-06-23 2009-01-07 Arbor Vita Corp METHOD AND COMPOSITIONS FOR MODULATING COX
RU2008131330A (ru) 2005-12-30 2010-02-10 Арбор Вита Корпорейшн (Us) Низкомолекулярные ингибиторы взаимодействия pdz
US8262847B2 (en) * 2006-12-29 2012-09-11 Lam Research Corporation Plasma-enhanced substrate processing method and apparatus
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Also Published As

Publication number Publication date
WO2009006548A3 (en) 2009-03-19
EP2175873A4 (en) 2011-10-05
CN101827604A (zh) 2010-09-08
US8008253B2 (en) 2011-08-30
WO2009006548A2 (en) 2009-01-08
AU2008272903A1 (en) 2009-01-08
JP2010532761A (ja) 2010-10-14
JP5775303B2 (ja) 2015-09-09
KR20100038366A (ko) 2010-04-14
US20090036376A1 (en) 2009-02-05
AU2008272903B2 (en) 2013-08-29
KR101604428B1 (ko) 2016-03-17
CA2692412A1 (en) 2009-01-08
EP2175873A2 (en) 2010-04-21
CN101827604B (zh) 2014-05-07
US8536129B2 (en) 2013-09-17
ES2555172T3 (es) 2015-12-29
US20120083449A1 (en) 2012-04-05
EP2175873B1 (en) 2015-11-11
AU2008272903A8 (en) 2010-05-06
DK2175873T3 (en) 2015-12-14
JP2014129353A (ja) 2014-07-10

Similar Documents

Publication Publication Date Title
CA2692412C (en) Treatment for anxiety
CA2724483C (en) Psd-95 inhibitor for the treatment of epilepsy
CA2657665C (en) Method and compositions for treating stroke with fever
ES2446292T3 (es) Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
Klopstein et al. Beneficial effects of αB-crystallin in spinal cord contusion injury
Guijarro-Belmar et al. The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′, 5′-monophosphate (Epac) for central nervous system trauma
de Sousa Chambel Urinary Dysfunction After Spinal Cord Injury Resolving Neuronal Mechanisms Behind Neurogenic Detrusor Overactivity
Chambel Urinary dysfunction after spinal cord injury: resolving neuronal mechanisms behind neurogenic detrusor overactivity
Donev Ion Channels as Therapeutic Targets, Part B
Holdridge Investigating the Effects of Peripheral Nerve Injury on δ Opioid Receptor Expression and Function: Implications for the Treatment of Chronic Neuropathic Pain

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130620